With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 1 646,25 ₴, with a 24-hour trading volume of 19,41B ₴. The asset's market cap is 7,3T ₴, after moving 1.23% in the last day.
Tokenized Novo Nordisk A/S is trading at 1 641,46 ₴, with a tokenized market cap of 133,74M ₴ and a 24-hour trading volume of 34,54M ₴. The tokenized asset has moved 0.93% in the past 24 hours.